X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT LTD. AJANTA PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 24.6 -15.3 - View Chart
P/BV x 10.1 2.5 404.1% View Chart
Dividend Yield % 0.6 1.3 45.1%  

Financials

 AJANTA PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
WOCKHARDT LTD.
Mar-17
AJANTA PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,7201,129 152.3%   
Low Rs1,103627 175.9%   
Sales per share (Unadj.) Rs194.6363.1 53.6%  
Earnings per share (Unadj.) Rs45.2-20.4 -221.2%  
Cash flow per share (Unadj.) Rs50.3-7.0 -721.1%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.1 49.8%  
Book value per share (Unadj.) Rs132.0301.8 43.7%  
Shares outstanding (eoy) m88.77110.55 80.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.32.4 300.0%   
Avg P/E ratio x31.2-42.9 -72.7%  
P/CF ratio (eoy) x28.1-125.9 -22.3%  
Price / Book Value ratio x10.72.9 367.5%  
Dividend payout %17.7-48.9 -36.2%   
Avg Mkt Cap Rs m125,29997,063 129.1%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,5709,665 26.6%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m17,27540,146 43.0%  
Other income Rs m1661,143 14.6%   
Total revenues Rs m17,44241,289 42.2%   
Gross profit Rs m5,807128 4,536.9%  
Depreciation Rs m4511,489 30.3%   
Interest Rs m492,253 2.2%   
Profit before tax Rs m5,474-2,472 -221.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460-211 -691.6%   
Profit after tax Rs m4,014-2,260 -177.6%  
Gross profit margin %33.60.3 10,543.3%  
Effective tax rate %26.78.5 312.2%   
Net profit margin %23.2-5.6 -412.7%  
BALANCE SHEET DATA
Current assets Rs m7,63946,160 16.5%   
Current liabilities Rs m2,71519,258 14.1%   
Net working cap to sales %28.567.0 42.5%  
Current ratio x2.82.4 117.4%  
Inventory Days Days43101 42.9%  
Debtors Days Days7994 83.6%  
Net fixed assets Rs m6,91440,165 17.2%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m11,44232,814 34.9%   
Net worth Rs m11,72133,367 35.1%   
Long term debt Rs m14931,903 0.5%   
Total assets Rs m14,81489,687 16.5%  
Interest coverage x112.9-0.1 -116,282.5%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.4 260.5%   
Return on assets %27.40 -319,450.8%  
Return on equity %34.2-6.8 -505.6%  
Return on capital %46.5-0.3 -13,880.6%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,4229,121 114.3%   
Fx outflow Rs m1,6782,133 78.7%   
Net fx Rs m8,7446,988 125.1%   
CASH FLOW
From Operations Rs m3,264-2,695 -121.1%  
From Investments Rs m-2,093-6,863 30.5%  
From Financial Activity Rs m-1,18612,545 -9.5%  
Net Cashflow Rs m-153,010 -0.5%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DISHMAN PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 22, 2018 03:13 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS